

# Juliane Häfner-Rieber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9053695/publications.pdf>

Version: 2024-02-01

54  
papers

840  
citations

430874

18  
h-index

580821

25  
g-index

56  
all docs

56  
docs citations

56  
times ranked

944  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy: oncologic outcomes and prognostic factors. <i>Tumori</i> , 2023, 109, 112-120.	1.1	3
2	Stereotactic body radiotherapy of lymph node metastases under MR-guidance: First clinical results and patient-reported outcomes. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 56-65.	2.0	8
3	Stereotactic radiosurgery for brain metastases from pelvic gynecological malignancies: oncologic outcomes, validation of prognostic scores, and dosimetric evaluation. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 172-180.	2.5	2
4	Influence of photon, proton and carbon ion irradiation on differentiation, maturation and functionality of dendritic cells. <i>Frontiers in Bioscience - Scholar</i> , 2022, 14, 1.	2.1	5
5	Quality assurance for online adaptive magnetic resonance guided radiation therapy: A software tool to complement secondary dose calculation and failure modes discovered in clinical routine. <i>Journal of Applied Clinical Medical Physics</i> , 2022, 23, e13523.	1.9	14
6	SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes. <i>Radiotherapy and Oncology</i> , 2022, 168, 106-112.	0.6	10
7	Secondary Malignancy Risk Following Proton vs. X-ray Radiotherapy of Thymic Epithelial Tumors: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. <i>Cancers</i> , 2022, 14, 2409.	3.7	2
8	Return to Work, Fatigue and Cancer Rehabilitation after Curative Radiotherapy and Radiochemotherapy for Pelvic Gynecologic Cancer. <i>Cancers</i> , 2022, 14, 2330.	3.7	3
9	Radiation-induced contrast enhancement following proton radiotherapy for low-grade glioma depends on tumor characteristics and is rarer in children than adults. <i>Radiotherapy and Oncology</i> , 2022, 172, 54-64.	0.6	9
10	Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3). <i>Radiation Oncology</i> , 2022, 17, .	2.7	11
11	Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patients' and Physicians' Assessment from the Randomized IMRT-MC2 Trial. <i>Cancers</i> , 2022, 14, 3010.	3.7	1
12	Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial). <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1311-1324.	0.8	37
13	Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John's wort skin oil. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 644-649.	2.0	5
14	Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands. <i>Cancers</i> , 2021, 13, 124.	3.7	1
15	MR-guided radiotherapy of moving targets. <i>Der Radiologe</i> , 2021, 61, 39-48.	1.7	6
16	A practical implementation of risk management for the clinical introduction of online adaptive Magnetic Resonance-guided radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 53-57.	2.9	28
17	Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Tumors: Initial Clinical Experience and Patient-Reported Outcomes. <i>Frontiers in Oncology</i> , 2021, 11, 610637.	2.8	31
18	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. <i>Radiotherapy and Oncology</i> , 2021, 159, 146-154.	0.6	37

#	ARTICLE	IF	CITATIONS
19	Patient positioning and immobilization procedures for hybrid MR-Linac systems. <i>Radiation Oncology</i> , 2021, 16, 183.	2.7	26
20	Innovative radiation oncology Together“ Precise,“Personalized,“Human. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1043-1048.	2.0	7
21	Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial. <i>Radiotherapy and Oncology</i> , 2021, 163, 165-176.	0.6	7
22	Effectiveness and Toxicity of Fractionated Proton Beam Radiotherapy for Cranial Nerve Schwannoma Unsuitable for Stereotactic Radiosurgery. <i>Frontiers in Oncology</i> , 2021, 11, 772831.	2.8	5
23	Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations. <i>Frontiers in Oncology</i> , 2021, 11, 757031.	2.8	17
24	Screening and Psycho-Oncological Support for Patients With Head and Neck Cancer and Brain Malignancies Before Radiotherapy With Mask Fixation: Results of a Feasibility Study. <i>Frontiers in Psychology</i> , 2021, 12, 760024.	2.1	1
25	Postoperative Radiotherapy for Endometrial Cancer in Elderly (≥80 Years) Patients: Oncologic Outcomes, Toxicity, and Validation of Prognostic Scores. <i>Cancers</i> , 2021, 13, 6264.	3.7	2
26	Estimation of the $\hat{\mu}/\hat{\sigma}^2$ ratio of non-small cell lung cancer treated with stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 142, 210-216.	0.6	22
27	Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors. <i>Cancers</i> , 2020, 12, 2862.	3.7	3
28	Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer“ Cross-Sectional Study of Eligibility and Administration Rates. <i>Frontiers in Oncology</i> , 2020, 10, 586449.	2.8	15
29	Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. <i>Radiation Oncology</i> , 2020, 15, 235.	2.7	13
30	Validation of Nine Different Prognostic Grading Indexes for Radiosurgery of Brain Metastases in Breast Cancer Patients and Development of an All-Encompassing Prognostic Tool. <i>Frontiers in Oncology</i> , 2020, 10, 1557.	2.8	4
31	Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme. <i>Clinical Lung Cancer</i> , 2020, 22, 332-340.e3.	2.6	11
32	Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung. <i>Frontiers in Oncology</i> , 2020, 10, 564857.	2.8	19
33	Adjuvant Radiation Therapy for Male Breast Cancer“ A Rare Indication?. <i>Cancers</i> , 2020, 12, 3645.	3.7	1
34	Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 705-714.	2.0	8
35	Fatigue following radiotherapy of low-risk early breast cancer “ a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419). <i>Radiation Oncology</i> , 2020, 15, 134.	2.7	5
36	Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 579-586.	0.8	40

#	ARTICLE	IF	CITATIONS
37	Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 987.	2.8	19
38	Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. <i>Frontiers in Oncology</i> , 2020, 10, 989.	2.8	15
39	Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. <i>Radiation Oncology</i> , 2020, 15, 30.	2.7	36
40	Accelerated Partial Breast Irradiation: A New Standard of Care?. <i>Breast Care</i> , 2020, 15, 136-147.	1.4	14
41	MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?. <i>Frontiers in Oncology</i> , 2020, 10, 615697.	2.8	6
42	First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 691-698.	2.0	44
43	Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. <i>Clinical Lung Cancer</i> , 2019, 20, e667-e677.	2.6	33
44	Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 312-319.	0.9	15
45	&lt;p&gt;Outcome and prognostic factors following palliative craniospinal irradiation for leptomeningeal carcinomatosis&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 789-801.	1.9	35
46	Acute Toxicity and Early Oncological Outcomes After Intraoperative Electron Radiotherapy (IOERT) as Boost Followed by Whole Breast Irradiation in 157 Early Stage Breast Cancer Patients – First Clinical Results From a Single Center. <i>Frontiers in Oncology</i> , 2019, 9, 384.	2.8	9
47	Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 677-687.	2.0	13
48	Response rates and recurrence patterns after low-dose radiotherapy with 4 Gy in patients with low-grade lymphomas. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 454-461.	2.0	22
49	Outcome and prognostic factors in single brain metastases from small-cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 98-106.	2.0	21
50	Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy. <i>Cancer Management and Research</i> , 2018, Volume 10, 6563-6569.	1.9	31
51	Whole brain radiation therapy alone versus radiosurgery for patients with 10 brain metastases from small cell lung cancer (ENCEPHALON Trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 388.	1.6	25
52	Palliative Radiotherapy for Leptomeningeal Carcinomatosis – Analysis of Outcome, Prognostic Factors, and Symptom Response. <i>Frontiers in Oncology</i> , 2018, 8, 641.	2.8	32
53	Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy. <i>Radiation Oncology</i> , 2017, 125, 317-324.	0.6	41
54	Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer – Experiences from a Single Institution. <i>Frontiers in Oncology</i> , 2017, 7, 215.	2.8	9